Climb Bio Inc (CLYM) Cash Flow Statement
Where CLYM’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$54.4M
- Capital expenditures
- $186,000
- Free cash flow
- −$54.5M
- Returned to shareholders
- —
- Change in cash
- −$51.5M cash at year-end $35.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CLYM operating cash flow, capex and free cash flow
CLYM cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$5.0M2019 | −$54.4M2025 | — | |
| Capital expenditures | $02019 | $186,0002025 | — | |
| Free cash flow | −$5.0M2019 | −$54.5M2025 | — | |
| Stock-based compensation | $707,0002020 | $8.1M2025 | +62.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CLYM cash flow by activity
CLYM net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CLYM cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$59.9M | −$73.9M | −$35.1M | −$45.2M | −$47.5M | −$20.7M | −$6.5M |
| Depreciation & amortization | $97,000 | $0 | — | — | — | — | — |
| Stock-based compensation | $8.1M | $5.6M | $12.8M | $7.0M | $3.7M | $707,000 | — |
| Change in working capital | −$601,000 | $1.7M | $3.8M | $210,000 | −$4.2M | −$2.9M | −$309,000 |
| Other non-cash items | −$2.1M | $51.1M | −$2.0M | $674,000 | $11.8M | $8.8M | $1.8M |
| Cash from operating activities | −$54.4M | −$15.6M | −$20.6M | −$37.4M | −$36.1M | −$14.1M | −$5.0M |
| Investing activities | |||||||
| Capital expenditures | −$186,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | $3.0M | −$121.1M | $69.0M | $34.4M | −$115.0M | $8.1M | — |
| Acquisitions & other investing | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Cash from investing activities | $2.8M | −$121.1M | $69.0M | $34.4M | −$115.0M | $8.1M | — |
| Financing activities | |||||||
| Shares issued | $0 | $119.8M | $0 | $0 | $177.1M | $4.9M | $0 |
| Other financing | −$21,000 | $11.0M | $841,000 | $0 | $149,000 | $0 | $26.2M |
| Cash from financing activities | −$21,000 | $130.7M | $841,000 | $0 | $177.2M | $4.9M | $26.2M |
| Summary | |||||||
| Net change in cash | −$51.5M | −$5.9M | $49.5M | −$3.3M | $26.4M | −$736,000 | $21.2M |
| Cash at end of period | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M | $20.5M | $21.2M |
| Free cash flow | −$54.5M | −$15.6M | −$20.6M | −$37.4M | −$36.1M | −$14.1M | −$5.0M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$13.5M | −$13.7M | −$17.5M | −$12.9M | −$8.7M | −$20.8M | −$8.4M | −$8.9M | −$54.9M | −$1.7M | −$3.6M | −$4.0M |
| Depreciation & amortization | $33,000 | $38,000 | $30,000 | $29,000 | $38,000 | $0 | — | $0 | — | — | — | — |
| Stock-based compensation | $1.5M | $1.6M | $1.0M | $4.0M | $1.0M | $2.0M | $1.7M | $2.9M | $512,000 | $465,000 | $1.2M | $656,000 |
| Change in working capital | $1.8M | −$2.1M | $1.3M | −$2.8M | −$3.0M | $3.9M | $1.7M | −$1.3M | $2.0M | −$640,000 | $1.4M | $7.5M |
| Other non-cash items | −$403,000 | −$226,000 | −$459,000 | −$468,000 | −$522,000 | −$606,000 | −$435,000 | −$268,000 | $51.7M | $53,000 | $71,000 | −$671,000 |
| Cash from operating activities | −$10.5M | −$14.4M | −$15.6M | −$12.1M | −$11.1M | −$15.4M | −$5.5M | −$7.6M | −$667,000 | −$1.8M | −$947,000 | $3.5M |
| Investing activities | ||||||||||||
| Capital expenditures | −$260,000 | $0 | $0 | −$109,000 | −$77,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | −$57.0M | −$13.0M | $25.5M | $15.3M | $4.8M | −$42.8M | −$53.4M | −$71.8M | −$9.6M | $13.8M | $36.7M | $28.0M |
| Acquisitions & other investing | $0 | $0 | $0 | $109,000 | $77,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from investing activities | −$57.3M | −$13.0M | $25.5M | $15.3M | $4.8M | −$42.8M | −$53.4M | −$71.8M | −$9.6M | $13.8M | $36.7M | $28.0M |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $103.7M | $5,000 | −$21,000 | $0 | $0 | $0 | $41,000 | $2.3M | $128.4M | $15,000 | $288,000 | $528,000 |
| Cash from financing activities | $103.7M | $5,000 | −$21,000 | $0 | $0 | $0 | $41,000 | $2.3M | $128.4M | $15,000 | $288,000 | $528,000 |
| Summary | ||||||||||||
| Net change in cash | $35.8M | −$27.3M | $9.9M | $3.1M | −$6.3M | −$58.2M | −$58.9M | −$77.0M | $118.1M | $11.9M | $35.8M | $32.1M |
| Cash at end of period | $44.1M | $8.4M | $35.7M | $25.8M | $22.7M | $29.0M | $87.2M | $146.2M | $223.1M | $105.0M | $93.1M | $57.4M |
| Free cash flow | −$10.8M | −$14.4M | −$15.6M | −$12.2M | −$11.2M | −$15.4M | −$5.5M | −$7.6M | −$667,000 | −$1.8M | −$947,000 | $3.5M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CLYM cash generation
In fiscal 2025 (ended December 31, 2025), Climb Bio generated -$54.4 million of cash from operations and spent $0.2 million on capital expenditures, leaving free cash flow of -$54.5 million. Cash and equivalents fell by $51.5 million over the year.
Related: CLYM income statement, CLYM balance sheet. See the CLYM stock overview for the latest quote and news.
CLYM cash flow FAQ
What is Climb Bio's free cash flow?
Climb Bio's free cash flow was -$54.5 million in fiscal 2025: -$54.4 million of operating cash flow minus $0.2 million of capital expenditures It was -$15.6 million a year earlier..
How much cash does Climb Bio generate from operations?
Climb Bio generated -$54.4 million of cash from operating activities in fiscal 2025.
How much does Climb Bio spend on capital expenditures?
Climb Bio spent $0.2 million on capital expenditures in fiscal 2025.